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OBJECTIVES: Hemophagocytic lymphohistiocytosis is a life-threatening 
hyperinflammatory disorder that is associated with high morbidity and mor-
tality in the ICU. It has also been associated with acute liver failure.
DESIGN: Retrospective observational study.
SETTING: Tertiary-care medical ICU.
PATIENTS: Thirty-one patients critically ill with hemophagocytic 
lymphohistiocytosis.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We performed a compre-
hensive review of critically ill hemophagocytic lymphohistiocytosis patients 
admitted to a tertiary-care medical ICU from January 2012 to December 
2018. Most patients presented with constitutional symptoms and elevated 
liver enzymes and thrombocytopenia were common upon hospital admis-
sion. ICU admission laboratory and clinical variables were used to calculate 
Acute Physiology and Chronic Health Evaluation II, hemophagocytic syn-
drome diagnostic score, and model for end‐stage liver disease. Mean age 
of the cohort was 48.1 years, and 45% were male. The mortality rate was 
65% at 28 days and 77% at 1 year. About 28-day survivors were younger, 
had lower mean Acute Physiology and Chronic Health Evaluation II score 
(16.5 vs 23.0; p = 0.004), and higher mean hemophagocytic syndrome 
diagnostic score (249.1 vs 226.0; p = 0.032) compared with nonsurvi-
vors. Survivors were less likely to receive mechanical ventilation, renal re-
placement therapy, or vasopressor support and were more likely to receive 
chemotherapy for hemophagocytic lymphohistiocytosis. In this ICU cohort, 
29% were diagnosed with acute liver failure, of whom only 22% developed 
acute liver failure early during their hospital stay. Acute liver failure was asso-
ciated with a higher model for end‐stage liver disease score upon hospital 
admission. Available histology in those that developed acute liver failure 
showed massive hepatic necrosis, or histiocytic or lymphocytic infiltrates.
CONCLUSIONS: Patients admitted to the ICU with hemophagocytic 
lymphohistiocytosis have a high mortality. Those who survived had lower 
Acute Physiology and Chronic Health Evaluation scores, had higher hemo-
phagocytic syndrome diagnostic scores, are more likely to receive hemo-
phagocytic lymphohistiocytosis specific chemotherapy, and are less likely 
to have organ failure. Hemophagocytic lymphohistiocytosis can be asso-
ciated with acute liver failure especially when model for end‐stage liver 
disease score is elevated upon admission.
KEY WORDS: hemophagocytic lymphohistiocytosis; hemophagocytic 
syndrome; hemophagocytic syndrome diagnostic score; intensive care 
unit mortality; liver failure; model for end‐stage liver disease
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Hemophagocytic syndrome, also referred to as hemophagocytic lymphohistiocytosis (HLH), is a life-threatening hyperinflammatory disorder 
first described in 1939 as histiocytic medullary reticulo-
sis. Primary HLH is a familial, X-linked disorder, result-
ing in uncontrolled activation in T-cells, macrophages, 
and inflammatory cytokines (1). Adults most commonly 
present with secondary HLH, which can develop in 
those with infection, malignancies, or autoimmune dis-
eases (2, 3). Described clinical presentations of HLH vary 
and include fever of unknown origin, sepsis like disease, 
vasculitis, neurologic abnormalities, and acute hepatitis 
with acute liver failure (ALF) (4, 5). Because HLH lacks 
unique clinical, pathologic, and laboratory features, its 
diagnosis has been largely based on the HLH-2004 cri-
teria, which weights clinical, laboratory, and biopsy 
histopathologic criteria observed with HLH (6). More 
recently, other differentially weighted diagnostic tools 
have been proposed for diagnosis, including the hemo-
phagocytic syndrome diagnostic score (HScore), which 
also includes clinical, laboratory, and pathologic data 
and omits laboratory values not commonly available, 
such as soluble interleukin-2 (sIL-2) receptor concentra-
tion and natural killer (NK) cell activity (3, 7). Although 
increasingly recognized in the critically ill adult patient 
population, some have suggested that HLH is an underdi-
agnosed cause of morbidity and mortality in the ICU (8). 
HLH may be underrecognized due to nonspecific symp-
toms, often attributed to sepsis. HLH associated with 
critical illness is thought to carry a high inhospital mor-
tality rate 60–68%, but timely diagnosis and treatment 
are believed to improve mortality (9, 10).
Elevated liver enzymes and hyperbilirubinemia are 
common in HLH (5), but ALF is reported to be as low 
as 1% (10). However, the true burden of HLH-associated 
ALF is not well characterized due to HLH underdiagnosis 
and the sparsity of larger case studies on HLH. The prev-
alence of ALF in HLH, and the clinical characteristics 
and prognosis of those who develop ALF is not known. 
Additionally, larger studies are needed to characterize 
further critically ill patients, investigate the pathophys-
iology of ALF in HLH, and validate prognostic factors 
and scoring systems such as HScore in this population.
The aim of this study is to determine the prev-
alence of ALF in HLH patients and correlate ad-
mission model for end‐stage liver disease (MELD) 
score, HScore, and other laboratory findings 
on the development of ALF in HLH patients. 
We also highlight patient outcomes, including mor-
tality, through a retrospective analysis using a large co-
hort of adult HLH patients cared for in a tertiary-care 
medical ICU. We hypothesized that HLH would be as-
sociated with a high mortality rate and a higher preva-
lence of liver failure than what previously reported.
MATERIALS AND METHODS
Patient Selection
A retrospective chart review was used to identify 
patients diagnosed with HLH admitted to the med-
ical ICU (MICU) at Indiana University Hospital, a 
large tertiary-care center in Indianapolis, IN, be-
tween January 2012 and December 2018. Patients 
with HLH were identified using billing codes D76.1 
(International Classification of Diseases [ICD], 10th 
Revision) and 288.4 (ICD-9th Revision). Of these, 
33 patients fulfilled HLH-2004 criteria (11) and two 
patients were further confirmed by autopsy findings 
(autopsy was performed due to the lack of clear cause 
of death and under family request). Patients younger 
than 18 years, without at least 1 year of follow-up or 
who did not meet HLH-2004 criteria, were excluded 
from the study. Patients missing laboratory values nec-
essary for this calculation (two patients) were excluded 
from analysis. A total of 31 patients were included in 
this study. This study was approved by the Indiana 
University Institutional Review Board (protocol 
number 1702323811).
Data Collection and Outcomes
Clinical data, including patient demographics, past 
medical history, substance use, medications, clin-
ical symptoms, laboratory data, and follow-up, were 
obtained from review of the electronic medical record. 
HLH was defined by meeting five out of eight HLH-
2004 criteria: fever, splenomegaly, cytopenias affecting 
greater than or equal to two peripheral blood lineages, 
hypertriglyceridemia and/or hypofibrinogenemia, 
hemophagocytosis in bone marrow or spleen or lymph 
nodes, low or absent NK cell activity, ferritin greater 
than or equal to 500 mg/L, and soluble CD25 greater 
than or equal to 2,400 U/mL (6). All laboratory and 
pathologic assessments were performed at Indiana 
University except sIL-2 and NK functions, which were 
the send-out studies to Cincinnati Children Hospital. 
Observational Study
Critical Care Explorations www.ccejournal.org     3
The date of diagnosis was defined as the first mention 
of HLH diagnosis or initiation of treatment for sus-
pected disease. Acute Physiology and Chronic Health 
Evaluation (APACHE) II score was calculated using 
data from the time of admission to the MICU (12). 
ALF was defined as an episode of acute hepatitis with 
total bilirubin greater than 3 mg/dL, coagulopathy (in-
ternational normalized ratio [INR] > 1.5), and hepatic 
encephalopathy in a patient with a previously normal 
INR without preexisting cirrhosis (13). HScore was 
calculated from data collected during MICU admis-
sion (7). MELD score was calculated using five clinical 
and laboratory variables upon admission to our hos-
pital (14).
The primary outcome was 28-day mortality after di-
agnosis in HLH patients and those HLH patients with 
ALF. Secondary outcomes included 1-year mortality, 
HScore, time to diagnosis from the start of symptoms, 
presence of ALF, need for mechanical ventilation, need 
for continuous renal replacement therapy, and need 
for vasopressor medications.
Statistical Analysis
Mean and sd were used to describe normally distrib-
uted continuous variables, whereas categorical vari-
ables were displayed as a percentage. Median and 
interquartile range were determined for nonnormally 
distributed continuous variables. Analysis of variance 
was used to compare different continuous variables be-
tween different groups. Chi-square or Fisher exact test 
(if expected values were low) was used to compare cat-
egorical data. Results were considered to have statis-
tical significance for two-sided p values less than 0.05.
RESULTS
A total of 31 patients were included in the final analysis. 
The median age of the cohort was 52 years (range, 19–84 
yr), with 55% female. Demographics, clinical presenta-
tion, and laboratory data of the cohort are described 
in Table 1. The median time between symptom/illness 
onset and diagnosis was 21 days (range, 2–224 d). The 
most common symptoms at presentation were consti-
tutional symptoms (fever, fatigue, and malaise) in 71% 
of the patients followed by gastrointestinal symptoms 
(32%), rash and jaundice (16% each), encephalop-
athy (6%), and chest pain (3%). Patients commonly 
presented with thrombocytopenia in 84% of patients 
and elevation of liver enzymes, including aspartate 
transaminase (AST) in 77%, alanine transaminase 
(ALT) in 52%, alkaline phosphatase in 61%, and total 
bilirubin in 77%. As expected, the mean serum fer-
ritin (29,533 ± 34,131 ng/mL) and sIL-2 receptor con-
centrations (19,956 ± 22,916 u/mL) were elevated in 
these patients. Mean HScore was 234.5 ± 28.3 (range, 
165–274). The mortality rate of the cohort was 65% at 
28 days and 77% at 1 year. Medical conditions trigger-
ing HLH, along with their prevalence and mortality, 
are described in Table 2. The most common cause of 
HLH was infection (45%), followed by malignancy 
(35%), the majority of which were hematologic malig-
nancies (32% of all HLH cases), and finally autoim-
mune disease (5%) of the patients. There was no clear 
etiology identified in 16% of the cohort.
Factors Characterizing HLH Survival at 28 Days 
From Diagnosis
Comparisons between the HLH patients who were 
alive or dead at 28 days are presented in Table  3. 
Compared with nonsurvivors, HLH survivors were 
on average younger than nonsurvivors (38.1 vs 53.6 
yr; p =0.035), had lower mean APACHE II score (16.5 
vs 23.0; p = 0.004), and had a higher mean HScore 
(249.1 vs 226.0; p = 0.032). HLH survivors were less 
likely to receive mechanical ventilation (27.3% vs 90%; 
p = 0.001), had fewer vasopressor needs (45.5% vs 95.0%; 
p = 0.004), and were less likely to receive renal replacement 
therapy (18.2% vs 65.0%; p = 0.023). HLH survivors at 28 
days had a lower prevalence of ALF than those who died, 
but this trend did not reach statistical significance (9.1% vs 
40.0%; p = 0.106). Although the average duration between 
symptom onset and diagnosis appeared to be shorter in 
the survivors’ group, the difference was not statistically 
significant (5.3 vs 6.5 wk; p = 0.687). Finally, those who 
survived were more likely to be treated with chemotherapy 
as part of their HLH directed therapy (81.8% vs 35.0%; 
p = 0.023).
Table  4 shows the individual characteristics of 
patients with liver failure. ALF was diagnosed in nine 
HLH patents (29%), of whom only two developed 
ALF early during their hospital stay. All patients who 
were diagnosed of ALF died within 1 year of HLH di-
agnosis, and the majority (89%) died within 28 days. 
Liver biopsy was performed in 44% (four of nine) 
patients, as clinically indicated (Table 5). Findings on 
liver histopathology included massive hepatic necrosis 
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TABLE 1. 
Characteristics of Adults Diagnosed With Hemophagocytic Lymphohistiocytosis During 
Medical ICU Admission
Characteristics
Adults With Hemophagocytic  
Lymphohistiocytosis (n = 31)
Gender, n (%)
 Male 14 (45)




 > 80 2
Symptoms, n (%)
 Constitutional (fever, malaise, and fatigue) 22 (71.0)
 Gastrointestinal (nausea, vomiting, and abdominal pain) 10 (32.3)
 Rash 5 (16.1)
 Jaundice 5 (16.1)
 Cough 5 (16.1)
 Encephalopathy 2 (6.5)
 Chest pain 1 (3.2)
Time (d) from symptoms onset to diagnosis,  
median (interquartile range, range)
21.0 (44.5, 2–224)
Acute Physiology and Chronic Health Evaluation II,  
mean ± sd (median, range)
20.6 ± 6.3 (6–32)
Admission laboratory values, mean ± sd (range)
 Platelets (1,000/mm3) 110.1 ± 123.8 (8–528)
 Hemoglobin (gm/dL) 10.4 ± 2.4 (6–15.6)
 WBC (1,000/mm3) 10.7 ± 23.0 (0.2–130)
 Alkaline phosphatase (u/L) 264.0 ± 231.1 (18–1,092)
 Aspartate transaminase (u/L) 603.9 ± 1,518.1 (13–8,270)
 Alanine transaminase (u/L) 231.6 ± 394.8 (5–1,773)
 Total bilirubin (mg/dL) 7.1 ± 10.3 (0.4–53)
Diagnostic laboratory values, mean ± sd (range)
 Soluble interleukin-2 receptor (U/mL) 19,955.7 ± 22,916.3 (1,536–95,716)
 Ferritin (ng/mL) 29,532.9 ± 34,131.1 (1,765–138,705)
 Triglycerides (mg/dL) 377.9 ± 638.9 (73–3,722)
 Fibrinogen (mg/dL) 180.8 ± 131.3 (50–684)
Hemophagocytic syndrome diagnostic score, mean ± sd (range) 234.5 ± 28.3 (165–274)
Treatment, % (n)
IV steroid 90 (28)
Chemotherapy (including etoposide) 51 (16)
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TABLE 2. 
Etiology of Hemophagocytic Lymphohistiocytosis
Etiology Prevalence, n (%) 28-d Mortality, % 1-yr Mortality
Infectious etiology 13 (45) 69 69
 Viral 9 (29) 78 78
 Bacterial 3 (10) 67 67
 Fungal 1 (3) 0 0
Malignancy 11 (35) 64 91
 Hematologic 10 (32) 60 90
 Solid (germ cell) tumor 1 (3) 100 100
Autoimmune disease 2 (6) 50 50
Idiopathic 5 (16) 60 80
TABLE 3. 
Characteristics of Patients Based on Survival at 28 d
Characteristics
Survivors at  
28 d (n = 11)
Deceased at  
28 d (n = 20) p
Age 38.1 53.6 0.035
WBC (1,000/mm3) 4.6 14.1 0.286
Hemoglobin (gm/dL) 9.8 10.7 0.333
Platelets (1,000/mm3) 133.2 97.4 0.451
Aspartate transaminase (u/L) 404.5 713.6 0.563
Alanine transaminase (u/L) 246.9 223.2 0.934
Total bilirubin (mg/dL) 3.4 9.2 0.132
Acute Physiology and Chronic Health Evaluation II score 16.5 23.0 0.004
Soluble interleukin-2 receptor (U/mL) 13,680.1 25,626.4 0.230
Ferritin (ng/mL) 32,271.0 29,198.4 0.821
Fibrinogen (mg/dL) 220.5 157.8 0.221
Hemophagocytic syndrome diagnostic score 249.1 226.0 0.032
Time from symptoms to diagnosis (wk) 5.3 6.5 0.687
Need for mechanical ventilation 27.3% 90% 0.001
Need for continuous renal replacement therapy 18.2% 65% 0.023
Need for vasopressor 45.5% 95% 0.004
Acute liver failure 9.1% 40% 0.106
Steroid treatment 100% 85% 0.1745
Chemotherapy treatment 81% 35% 0.023
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(MHN) (2), histiocytic infiltrates (1), and lymphocytic 
infiltrates (1). Patients who developed ALF had ele-
vated transaminases (AST and ALT) and MELD score 
upon admission to the hospital and were more likely 
to require mechanical ventilation compared with those 
who did not develop ALF.
DISCUSSION
HLH is a hyperinflammatory autoimmune syndrome 
that leads to multiple organ failure in the ICU. The 
systemic inflammation associated with HLH explains 
why fever and constitutional symptoms are the most 
common presenting symptoms in our study at 71%, 
similar to but lower than the up to 90% reported in 
other studies (3, 7, 10, 15). Most presenting symptoms 
are nonspecific and they can easily be confused with 
infections, autoimmune disease, or any kind of inflam-
matory state, which may explain the prolonged time 
between symptom onset and the confirmed diagnosis. 
The diagnosis of HLH has largely been based on HLH-
2004 criteria, which includes sIL-2 and NK function 
as diagnostic criteria. These tests are often performed 
off-site, as was the case for our patients, taking days 
to weeks to return, limiting their utility in early HLH 
diagnosis (1). For these reasons, the HScore is often 
a more practical tool to estimate an individual’s risk 
of HLH (3, 7). All patients but one had an HScore 
TABLE 4. 



















1 21 25 47 45 15.8 Germ cell tumor Yes Massive hepatic  
necrosis
2 66 36 2,096 638 9.4 Idiopathic Yes No
3 75 33 96 268 53.0 Idiopathic Yes No
4 33 24 8,270 1,773 2.8 Herpes simplex 
virus viremia
Yes No
5 35 25 97 98 7.1 Idiopathic Yes Massive hepatic  
necrosis




7 65 19 23 23 5.0 Myelodysplastic  
syndrome
No Increased histiocytic 
infiltrate and  
increased  
Kupffer cells
8 60 35 615 147 4.2 Epstein-Barr virus Yes No
9 27 23 389 161 9.0 Diffuse large  
B-cell  
lymphoma
Yes Diffuse involvement  
by abnormal  
lymphoid  
proliferation  
(related to  
lymphoma)
aLaboratory tests upon hospital admission.
All patients were on mechanical ventilation and a vasopressor.
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greater than 169, the proposed cutoff value for diag-
nosing HLH, giving a sensitivity of 97% (7). On the 
other side, Saeed et al (16) proposed a ferritin cutoff of 
3,951 ng/mL in critically ill patients to improve the di-
agnostic utility of HLH. That cutoff would have missed 
five patients (16%) in our cohort, suggesting that this 
cutoff may not be sensitive enough alone to diagnose 
HLH in adult critically ill patients. Additionally, ele-
vated ferritin concentrations are not specific to HLH, 
being associated with renal failure, liver injury, infec-
tions, and hematologic malignancies, and studies have 
described a low specificity of elevated ferritin concen-
trations alone as a screening tool for HLH (17).
In our study, critically ill HLH patients had a high 
mortality of 65% at 28 days after HLH diagnosis. Higher 
APACHE II score, older age, and organ failure were as-
sociated with a higher mortality rate, consistent with 
that observed in a general ICU population (18, 19). 
Although APACHE II score is proven to predict hospital 
mortality rate in sepsis, it is notable that these patients 
had a higher mortality rate than what expected from 
their APACHE II score (20). A smaller study from India 
TABLE 5. 
Characteristics of Patients With and Without Acute Liver Failure
Characteristics
ALF, n = 9,  
Mean (sd)
No ALF, n = 22,  
Mean (sd) p
Age (yr) 45.0 (20) 49.0 (19) 0.589
Alkaline phosphatase (u/L)a 331.9 (201) 237.4 (241.7) 0.358
Aspartate transaminase (u/L)a 1,435.3 (2,504.4) 264.0 (432) 0.049
Alanine transaminase (u/L)a 493.7 (591.9) 124.6 (176) 0.016
Total bilirubin (mg/dL)a 12.7 (15.6) 4.9 (6.3) 0.054
Model for end‐stage liver disease scorea 28.3 (6.3) 18.4 (7.9) 0.002
Acute Physiology and Chronic Health Evaluation II 21 (6.0) 20 (6.5) 0.846
Soluble interleukin-2 receptor (U/mL) 27,632.0 (30,635.1) 16,970.4 (18,765.6) 0.316
Ferritin (ng/mL) 34,655.4 (39,448.9) 27,437.3 (32,200.4) 0.607
Fibrinogen (mg/dL) 139.0 (52.6) 198.7 (153.7) 0.269
Hemophagocytic syndrome diagnostic score 223.4 (30.2) 238.5 (27.1) 0.209
Need for mechanical ventilation % (n) 100.0% (9) 54.5% (12) 0.030
Need for continuous renal replacement therapy % (n) 78% (7) 36.4% (8) 0.054
Need for vasopressor % (n) 100% (9) 68.2% (15) 0.077
28-d mortality % (n) 89% (8) 54.5% (12) 0.106
1-yr mortality % (n) 100% (9) 68.2% (15) 0.077
Biopsy results (4/9) n  
Massive necrosis 2
Increased histiocytic infiltrate and increased Kupffer cells 1
Diffuse involvement by abnormal lymphoid proliferation  
(related to lymphoma)
1
ALF = acute liver failure.
aAt the time of hospital admission.
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(n = 10) also had a similar presentation, where the mean 
APACHE II score was 17.4, but their ICU and inhospi-
tal mortality were, respectively, 70% and 80% (21). This 
simply could be due to deviation from the mean in a rel-
atively smaller sample, but it may also reflect the fact that 
the hyperinflammatory process in HLH causes more fu-
ture organ damage than expected in other patients with 
sepsis and similar APACHE II score.
ALF was common in our HLH cohort, diagnosed in 
nine of 31 patients (29%). This is higher than what has 
been reported, with other studies describing only 1% and 
7% as developing ALF during ICU admission (9, 10). 
This finding could be due to the differences in the patient 
cohort; Indiana University hospital is a referral center 
for liver transplant. All ALF patients had elevated liver 
enzymes and bilirubin upon hospital admission; how-
ever, the indication for admission included liver failure 
in only two HLH patients in our analysis. The remaining 
seven cases of ALF developed after hospital admission 
and may represent clinical deterioration to multiple 
organ dysfunction, as most of these required mechanical 
ventilation, vasopressor support, and renal replacement 
therapy at some point during their hospital stay. Because 
these patients who developed ALF had a significantly 
higher AST, ALT, and MELD score upon admission to 
the hospital, it suggests that liver involvement may not 
simply be due to disease progression and likely started 
earlier in the disease process, prior to hospital admis-
sion. This suggests that clinician should consider a high 
MELD score and transaminases at admission to prevent 
delayed diagnosis of HLH in the settings of liver dys-
function, as has been suggested by others (22).
The etiology of ALF in adults with HLH has not 
been clearly defined. In our study, four of nine patients 
with ALF had a liver biopsy. The pathognomonic find-
ing of hemophagocytosis, histiocytic infiltrates, and 
increased Kupffer cells was found in only one of four 
liver biopsies. This finding itself is not enough to di-
agnose HLH, and one other study suggested that only 
half of their 12 patients with hepatic sinusoidal hemo-
phagocytosis met the 2004 HLH criteria (23). The find-
ing of lymphoma cell infiltration in one patient’s liver 
biopsy explains the liver failure and etiology of HLH 
in that case. In two patients, biopsy showed MHN, 
characterized by diffuse multilobular and panacinar 
hepatic necrosis (24). The exact mechanism of MHN 
is not well known, but it has been associated with viral 
hepatitis, autoimmune disease, and drug-induced liver 
injury (25). These findings suggest that HLH should 
be considered in liver failure or hepatitis cases without 
a clear etiology, particularly if they have other sup-
portive laboratory or clinical finding.
Treatment of HLH in ICU patients is challenging due 
to a high severity of illness and similar presentation to 
other critical illnesses. Primary treatment is supportive 
care and treatment of the causative disease if one is 
identified. Further therapies focus on decreasing the 
hyperinflammatory state. In our cohort, most patients 
were treated with standard of care corticosteroids, but 
only half of the patients were able to receive full HLH 
2004-recommended treatment, which includes admin-
istration of chemotherapeutic agents such as etoposide. 
As reported in previous studies, we found that patients 
who received chemotherapy with etoposide had a 
higher survival rate (18). However, sicker patients were 
less likely to receive chemotherapy, as evidenced by an 
average APACHE II score of 17.1 than 23.8 for those 
who received and did not receive etoposide. Therefore, 
it is difficult to conclude whether etoposide adminis-
tration itself improved survival or if the observed sur-
vival benefit was due to milder disease in the treatment 
group. Anakinra, a human interleukin (IL)-1 receptor 
antagonist protein, was used in one of our patients. 
Anakinra in combination with intravenous immuno-
globulin for treatment of HLH has been described in a 
small retrospective study, which found a 50% survival 
rate for ICU patients treated with this combination 
(26). Other proposed treatments for HLH include the 
anti-IL-6 antibody tocilizumab, which has been used 
for a number of diseases causing cytokine storm, most 
recently coronavirus disease 2019, in which severe di-
sease shares some characteristics with HLH (27, 28). 
Stem-cell transplant has also been suggested as a sal-
vage therapy and was used in one of our patients with 
HLH due to underlying lymphoma (27). Current rec-
ommendations suggest multidisciplinary input to tailor 
therapy to each patient depending on their comorbidi-
ties, HLH trigger, presentation, and severity of illness.
There are limitations to this study. First, it is a ret-
rospective analysis performed at a single tertiary-care 
center, a referral center for liver transplant. Due to the 
retrospective nature, data were collected from chart 
reviews and relied on documentation of symptoms 
and clinical findings, which due to their nonspecific 
nature may not have been recorded. The relatively 
small sample size and retrospective nature precluded 
Observational Study
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multivariate analysis. Furthermore, treatment and 
diagnostic algorithms reflect our single-center expe-
rience. Future prospective, multicenter studies are 
needed to confirm our findings, particularly the corre-
lation of high MELD score and elevated transaminases 
with early diagnosis of HLH-associated ALF and as 
markers of a poor prognosis in HLH.
CONCLUSIONS
HLH is a rare, life-threatening, and likely underrec-
ognized disease that carries very high mortality when 
diagnosed in critically ill patients. It should be sus-
pected in patients with constitutional symptoms and 
should be considered in patients who develop ALF, 
especially in the setting of elevated ferritin and high 
HScore. ALF may present early or late in the course 
of the disease especially in patients with high admis-
sion MELD score and carries a very high mortality. 
Treatments include targeted therapies to the trigger-
ing disease, and the use of corticosteroids and chemo-
therapeutic agents, but ICU patients diagnosed with 
HLH and ALF were often too sick to receive the all 
recommended therapies. Given the high mortality, fu-
ture studies should further explore the role for early 
screening for HLH and associated ALF and on the role 
of early, aggressive therapy in this population, particu-
larly with new therapies that may mitigate the adverse 
effects of traditional chemotherapies and therefore 
better tolerated by critically ill HLH patients.
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